Suggested remit - To appraise the clinical and cost effectiveness of nivolumab within its marketing authorisation for unresectable, advanced oesophageal cancer when standard chemotherapy has failed.
Status In progress
Process STA 2018
ID number 1249

Provisional Schedule

Expected publication 08 January 2020

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
06 July 2018 As you will be aware, the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of nivolumab for previously treated oesophageal cancer. Please note that the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in early December 2018.
06 February 2018 - 06 March 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
11 August 2017 In progress, In progress

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance